Q2 EPS Estimate for Pasithea Therapeutics Lifted by Analyst

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Equities researchers at HC Wainwright boosted their Q2 2026 EPS estimates for shares of Pasithea Therapeutics in a report issued on Thursday, May 21st. HC Wainwright analyst S. Nik now expects that the company will earn ($0.16) per share for the quarter, up from their prior estimate of ($0.45). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Pasithea Therapeutics’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Pasithea Therapeutics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.76) EPS, FY2027 earnings at ($1.01) EPS and FY2028 earnings at ($1.30) EPS.

Pasithea Therapeutics (NASDAQ:KTTA) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.33.

Several other research firms also recently commented on KTTA. Zacks Research downgraded shares of Pasithea Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, April 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

Pasithea Therapeutics Price Performance

KTTA stock opened at $0.70 on Monday. The firm’s fifty day simple moving average is $0.76 and its 200-day simple moving average is $0.85. The company has a market capitalization of $17.45 million, a P/E ratio of -0.34 and a beta of 0.22. Pasithea Therapeutics has a 12 month low of $0.28 and a 12 month high of $2.06.

Institutional Trading of Pasithea Therapeutics

Several large investors have recently made changes to their positions in KTTA. Janus Henderson Group PLC purchased a new stake in shares of Pasithea Therapeutics in the 4th quarter valued at $2,720,000. Vivo Capital LLC purchased a new stake in Pasithea Therapeutics during the fourth quarter worth $2,709,000. Squadron Capital Management LLC purchased a new stake in Pasithea Therapeutics during the fourth quarter worth $2,709,000. Adage Capital Partners GP L.L.C. purchased a new stake in Pasithea Therapeutics during the fourth quarter worth $2,709,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Pasithea Therapeutics during the fourth quarter worth $375,000. 23.92% of the stock is owned by hedge funds and other institutional investors.

About Pasithea Therapeutics

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.